MDT

87.93

+1.17%↑

VEEV

281.03

-0.66%↓

119.21

+0.2%↑

HQY

103.63

-1.89%↓

PHR.US

28.29

+0.07%↑

MDT

87.93

+1.17%↑

VEEV

281.03

-0.66%↓

119.21

+0.2%↑

HQY

103.63

-1.89%↓

PHR.US

28.29

+0.07%↑

MDT

87.93

+1.17%↑

VEEV

281.03

-0.66%↓

119.21

+0.2%↑

HQY

103.63

-1.89%↓

PHR.US

28.29

+0.07%↑

MDT

87.93

+1.17%↑

VEEV

281.03

-0.66%↓

119.21

+0.2%↑

HQY

103.63

-1.89%↓

PHR.US

28.29

+0.07%↑

MDT

87.93

+1.17%↑

VEEV

281.03

-0.66%↓

119.21

+0.2%↑

HQY

103.63

-1.89%↓

PHR.US

28.29

+0.07%↑

Home・Akcijų sąrašas・Minerva Neurosciences Inc

Minerva Neurosciences Inc

Uždarymo kaina

1.69 -2.87

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.68

Max

1.74

Pagrindiniai rodikliai
By Trading Economics
P/E Sektoriaus vid.	1.959 50.291
Darbuotojai	8

Dividendai
By Dow Jones
Kitas uždarbis	2025-08-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	2.2M 11M
Ankstesnė atidarymo kaina	4.56
Ankstesnė uždarymo kaina	1.69

Minerva Neurosciences Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-06-30 21:26; UTC

Pagrindinės rinkos jėgos

AeroVironment Shares Slide on Stock, Notes Offerings

2025-06-30 16:50; UTC

Įsigijimai, susijungimai, perėmimai

BBVA Won't Withdraw Sabadell Offer

2025-06-30 23:43; UTC

Rinkos pokalbiai

Gold Edges Higher, Underpinned by Fed-Rate Cut Hopes -- Market Talk

2025-06-30 23:38; UTC

Rinkos pokalbiai

Nikkei May Fall as Yen Has Strengthened Amid Trade Uncertainty -- Market Talk

2025-06-30 23:38; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-06-30 23:03; UTC

Uždarbis

Boeing CFO Exit Is Latest Change in Chief Executive Kelly Ortberg's C-Suite -- Update

2025-06-30 22:50; UTC

Įsigijimai, susijungimai, perėmimai

Giant Eagle Closes Sale of Its GetGo Business to Alimentation Couche-Tard

2025-06-30 22:50; UTC

Uždarbis

Boeing Hires Former Lockheed Martin Executive to Succeed CFO Brian West -- Update

2025-06-30 21:26; UTC

Uždarbis

Berkshire Stock Ends Quarter on Sour Note. It's About Even With S&P 500 So Far in 2025. -- Barrons.com

2025-06-30 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-06-30 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-06-30 19:46; UTC

Rinkos pokalbiai

Nike's Buzz is Back Amid Lean into Women Sports -- Market Talk

2025-06-30 19:16; UTC

Rinkos pokalbiai

Oil Futures Snap Winning Streak on OPEC+ Outlook -- Market Talk

2025-06-30 19:10; UTC

Rinkos pokalbiai

U.S. Natural Gas Wipes Out Friday's Gains -- Market Talk

2025-06-30 19:07; UTC

Rinkos pokalbiai

Dollar Ends Losing Quarter Facing Downward Pressure -- Market Talk

2025-06-30 18:27; UTC

Rinkos pokalbiai

Gold Has Largest Half-Year Gain Since 2007 -- Market Talk

2025-06-30 17:08; UTC

Įsigijimai, susijungimai, perėmimai

MicroStrategy Stock Jumps After Latest Bitcoin Purchase as Holdings Near 600,000 Tokens -- Barrons.com

2025-06-30 17:00; UTC

Įsigijimai, susijungimai, perėmimai

HPE Stock Soars as Juniper Merger Gets Regulatory Approval. There's Just 1 Catch. -- Barrons.com

2025-06-30 16:41; UTC

Rinkos pokalbiai

WTI Crude Undeperforms as U.S.-Canada Trade Talks to Resume -- Market Talk

2025-06-30 16:32; UTC

Rinkos pokalbiai

United Parks' Potential Buyback Resumption Could Be Catalyst For Stock -- Market Talk

2025-06-30 16:23; UTC

Įsigijimai, susijungimai, perėmimai

BBVA: Offer Remains in Effect in Accordance With Applicable Regulations

2025-06-30 16:22; UTC

Įsigijimai, susijungimai, perėmimai

BBVA Decided Not to Withdraw Offer for Banco De Sabadell

2025-06-30 16:20; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2025-06-30 16:20; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2025-06-30 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-06-30 16:07; UTC

Uždarbis

Umicore to Post 1H Results on Aug 1

2025-06-30 15:59; UTC

Rinkos pokalbiai

Copper Conditions Set to Remain Tight But Risks Loom -- Market Talk

2025-06-30 15:55; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Home Depot to Consolidate Pro Distribution with GMS Deal -- Market Talk

2025-06-30 15:54; UTC

Rinkos pokalbiai

Gold Futures Recoup Some Losses Though Demand Looks Set to Weaken -- Market Talk

2025-06-30 15:41; UTC

Įsigijimai, susijungimai, perėmimai

Google Bets Big on Nuclear Fusion With MIT Spinoff Commonwealth -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Minerva Neurosciences Inc Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių Minerva Neurosciences Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Apie bendrovę Minerva Neurosciences Inc

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.